Hypothesis

Administering alpha‑ketoglutarate (AKG) during the sleep phase enhances glymphatic clearance by promoting TET‑mediated demethylation of regulatory regions controlling aquaporin‑4 (AQP4) polarization and expression, thereby increasing CSF‑interstitial fluid exchange and nocturnal removal of amyloid‑β and tau.

Mechanistic Rationale

• AKG is an obligate cofactor for TET1/2/3 dioxygenases that oxidize 5mC to 5hmC, initiating active DNA demethylation [1].
• In neurons, TET activity drives demethylation of promoters for genes involved in water transport and glial function; reduced methylation of the Aqp4 locus correlates with heightened AQP4 membrane localization in astrocytes [3].
• Sleep drives a surge in interstitial CSF flow and upregulates AQP4 polarization via circadian‑controlled signaling pathways [2].
• AKG also suppresses mTOR signaling, which can relieve inhibition of autophagy‑lysosomal pathways that work alongside glymphatic flux [5]
• Combining these, nocturnal AKG availability could synchronize epigenetic remodeling with the sleep‑dependent clearance window, making the brain’s “autopsy” more efficient.

Testable Predictions

1. Mice receiving AKG (300 mg/kg i.p.) at ZT14 (onset of rest) will show a 2‑fold increase in CSF‑derived tracer influx into the cortex compared with vehicle‑treated controls, measured by fluorescent dextran imaging [2].
2. The same treatment will elevate hippocampal 5hmC levels at the Aqp4 promoter by ~30% relative to morning‑dosed AKG or night‑vehicle groups, assessed by dot‑blot or immunoprecipitation sequencing.
3. Enhanced tracer clearance will correlate with reduced amyloid‑β plaque load after 4 weeks of chronic nightly AKG dosing in APP/PS1 mice.
4. Pharmacological inhibition of TET activity (e.g., with Bobcat339) will abolish the AKG‑induced boost in glymphatic flux, confirming epigenetic mediation.

Experimental Design

• Subjects: Male C57BL/6J mice (3‑month old) and APP/PS1 transgenic line; n=8 per group.
• Groups: (1) Vehicle at ZT14, (2) AKG at ZT14, (3) AKG at ZT2 (active phase), (4) AKG+TET inhibitor at ZT14.
• Procedure: Administer compounds via intraperitoneal injection; 30 min later inject CSF‑traced fluorescent dextran (70 kDa) into the cisterna magna. After 90 min, perfuse, extract brains, quantify cortical tracer intensity via confocal microscopy. Parallel cohorts sacrificed for DNA hydroxymethylation assay at the Aqp4 promoter. Longitudinal cohort receives nightly AKG for 4 weeks; amyloid burden assessed by Thioflavin‑S staining.
• Analysis: Two‑way ANOVA (treatment × time) with post‑hoc Tukey; significance set at p<0.05.

If AKG’s benefit is contingent on sleep‑timed epigenetic remodeling, we predict a significant interaction where only nocturnal AKG elevates both 5hmC at Aqp4 and glymphatic influx, linking metabolite availability, TET activity, and the brain’s nightly self‑editing process.